Clinical Trial Update: Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial comparing tocilizumab to azathioprine in neuromyelitis optica spectrum disorders (NMOSD) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorders

Drugs mentioned

• Azathioprine (azathioprine)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Tianjin Medical University General Hospital | Conditions: Neuromyelitis Optica Spectrum Disorders, Neuromyelitis Optica | Phase 2, Phase 3 | Status: COMPLETED